Technology News and Research

RSS

Stem cell bandage human clinical trial for torn meniscal cartilage

The company behind a pioneering stem cell bandage, believed to be the world's first adult and autologous (patient's own) stem cell treatment designed to heal torn meniscal cartilage, can now take the technology to human clinical trials thanks to an investment from one of the UK's most successful entrepreneurs.

14 Nov 2011

Global demand to join pioneering adult stem cell study to treat ALS

BrainStorm Cell Therapeutics Inc., an innovative developer of adult stem cell technologies and CNS therapeutics, today announced that patients from across the globe are demanding to be included in the pioneering clinical study started earlier this year at Jerusalem's Hadassah University Medical Center.

14 Nov 2011

Functional MRI illuminates brain networks activated by motion

An estimated 300,000 people in North America are afflicted with dystonia, a disorder characterized by a progressive loss of motor control. Patients with generalized dystonia grapple with involuntary muscle spasms that lead to uncontrolled twisting and turning in awkward, sometimes painful postures.

14 Nov 2011

Decision Simulation licenses virtual patient platform from University of Pittsburgh

Decision Simulation LLC, the leading provider of web-based virtual patient platforms that enhance clinical decision-making skills, today announced it has extended its licensing agreement with the University of Pittsburgh.

14 Nov 2011

Great Basin seeks FDA 510(k) approval for C. difficile molecular diagnostic test

Great Basin Corporation, a privately held life sciences company developing sample-to-result molecular diagnostic solutions, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its first molecular diagnostic test for Clostridium difficile (C. diff).

14 Nov 2011

SANUWAVE Health third quarter revenues decrease 42% to $161,678

SANUWAVE Health, Inc. today reported financial results for the three and nine months ended September 30, 2011.

14 Nov 2011

Demand for non-drug intervention for atrial fibrillation will remain, despite FDA PVAC decision

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the search for an improved method of treating atrial fibrillation (AF) will be unaffected by the recent mixed decision by the Food and Drug Administration (FDA) panel on Medtronic's phased radiofrequency (RF) pulmonary vein ablation catheter (PVAC).

From Medtronic 14 Nov 2011

Cortex third quarter net loss increases to $1,175,000

Cortex Pharmaceuticals, Inc. reported a net loss of approximately $1,175,000, or $0.01 per share, for the quarter ended September 30, 2011, compared with a net loss of approximately $528,000, or $0.01 per share, for the corresponding prior year quarter.

14 Nov 2011

American Shared Hospital Services third quarter revenue increases to $9,148,000

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the third quarter and first nine months of 2011.

From Elekta 14 Nov 2011

Torax FENIX Continence Restoration System receives CE Mark

Torax Medical Inc. has received CE Mark for its FENIX Continence Restoration System, an innovative new approach to the treatment of fecal incontinence. Fecal Incontinence (FI) is the inability to control bowel movements.

14 Nov 2011

Leonardo Biosystems receives second investment from Texas Emerging Technology Fund

Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.

14 Nov 2011

Allscripts approves Apixio Community Search product

Apixio Inc., the leading provider of clinical integration and medically intelligent search solutions for private health data, announced that its Community Search product has been tested and approved by Allscripts and is now featured in the Allscripts Application Store and Exchange on the company's ClientConnect website. Apixio is available today for users of Sunrise Clinical Manager (SCM) 5.5.

14 Nov 2011

Soligenix third quarter revenues increase to $5,796,000

Soligenix, Inc., a development stage biopharmaceutical company, announced today its financial results for the third quarter of 2011.

14 Nov 2011

BioVentrix announces completion of enrollment in PliCath HF human clinical trial

BioVentrix, developer of the PliCath HF System, today announced the achievement of a significant milestone - completion of enrollment in its pilot human clinical trial. PliCath HF is a novel device which enables Epicardial Catheter-based Ventricular Restoration (ECVR).

14 Nov 2011

Nile Therapeutics third quarter net loss decreases to $1.1 million

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced its third quarter financial results for 2011.

14 Nov 2011

First Edition: November 14, 2011

In today's headlines, reports about the Supreme Court's expected health law announcement; about where things stand with the super committee and its fast-approaching deadline; and other health policy news.

14 Nov 2011

Luminescent upconversion nanocrystals can detect cancer cells

Upconversion emission materials are ideal for bioimaging due to its effectiveness as contrast agents for the detection of cancer cells, more so when the background emission of non-cancerous tissues can be minimised. These materials could be used as biomarkers for luminescent labeling of cancerous cells. Opaque tissues can be turned into glassy, transparent substances by using these biomarkers which rely on near-infrared excitation.

14 Nov 2011

Former soldier develops app to save lives of burns victims

A former soldier has developed an app which could save the lives of burns victims, both in combat and in hospitals around the world.

14 Nov 2011

BSP completes HyperQ technology clinical research study on CAD

BSP Biological Signal Processing Ltd. (BSP), which develops and manufactures products for the non-invasive, accurate diagnosis of Coronary Artery Disease (CAD), recently announced the successful completion of a comprehensive clinical research study evaluating the performance of the company's HyperQ technology in diagnosing CAD.

14 Nov 2011